CD19 and neoplasm: TriKEs, such as the 161519 TriKE (anti-CD16, IL-15, and anti-CD19), have been shown to significantly enhance NK cell proliferation, activation, cytokine secretion, and cytotoxicity against CD19+ tumor cells, leading to an improved tumor growth inhibition and prolonged survival in preclinical models of B-cell lymphoma (108).